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ABSTRACT 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
bevacizumab (avastin) is safe and effective as adjuvant chemotherapy for adult patients with 
stage IIIb or IV non-small cell lung carcinoma (NSCLC). 
STUDY DESIGN: Review of three randomized controlled trials (RCT) published in 2006, 2009, 
and 2011, all English language.  
DATA SOURCES: Two randomized, double-blind, controlled clinical trials comparing 
bevacizumab to placebo as adjunctive chemotherapy, and one RCT comparing bevacizumab as 
adjunctive chemotherapy versus the use of no adjunctive chemotherapy. All articles were found 
using PubMed, Medline, and OVID.  
OUTCOMES MEASURED: Overall survival (OS) and progression-free survival (PFS) were 
measured. OS was defined as time from randomization to death from any cause. PFS was 
defined as time from randomization to first documented disease progression or death on study 
treatment, whichever occurred first. Event-time distributions were estimated using the Kaplan-
Meier method. 
RESULTS: Herbst et al2 and Reck et al6 compared traditional chemotherapy plus bevacizumab 
to traditional chemotherapy plus placebo, and Sandler et al3 compared traditional chemotherapy 
plus bevacizumab to traditional chemotherapy alone. Herbst et al2 failed to find a significant 
difference in OS or PFS between subjects using adjuvant bevacizumab and those using 
traditional chemotherapy. Reck et al6 was unable to assess OS; however, the investigators 
reported that PFS was significantly improved with the addition of bevacizumab to traditional 
chemotherapy. Sandler et al3 established that the addition of bevacizumab to traditional 
chemotherapy has statistically significant survival benefits in patients with NSCLC. 
 
CONCLUSIONS: From the research performed and results obtained, the evidence is 
inconclusive and conflicting to support the use of bevacizumab as adjuvant chemotherapy for 
stage IIIb or IV NSCLC. With inconsistencies and differing results among the three RCTs, 
further research would be helpful to confirm or negate the question of whether bevacizumab is 
actually beneficial as adjuvant therapy. In addition to researching the efficacy and safety of 
bevacizumab as adjuvant chemotherapy, it would be advantageous to study the efficacy and 
safety of bevacizumab as monotherapy. Further research is warranted to obtain more conclusive 
data. 
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INTRODUCTION 
Malignant epithelial cells that form in the lung tissue cause non-small cell lung 
carcinoma (NSCLC), with the most common types being squamous cell carcinoma, large cell 
carcinoma, and adenocarcinoma. NSCLC may present as an incidental finding on chest imaging 
or with symptoms due to either local invasion or compression of adjacent thoracic structures. 
Common symptoms, which may be indicative, but are neither specific nor diagnostic for lung 
cancer, include hemoptysis, worsening cough, chest pain, weight loss, malaise, dyspnea, and/or 
hoarseness.1 As a class, NSCLCs are reasonably unresponsive to chemotherapy and radiation 
therapy. Nevertheless, the addition of bevacizumab as adjunctive treatment to traditional 
chemotherapy, has been investigated as an option for patients with NSCLC that is refractory to 
treatment.1 This paper evaluates three randomized controlled trials (RCT) comparing the efficacy 
and safety of bevacizumab (avastin) as adjuvant chemotherapy for adult patients with stage IIIb 
or IV NSCLC. 
NSCLC is a major cause of illness, disability, and death. Lung cancer is the leading cause 
of death worldwide, with more than 85% of lung cancers being NSCLC.1,2,3 Due to vague 
presenting symptoms or incidental findings on imaging, around 75% of NSCLC patients are 
initially diagnosed with advanced metastatic disease.2 National cancer care expenditure for lung 
cancer is an estimated $12.12 billion, with lost time and economic productivity being greatest for 
adults aged 20 years and older.4 Lung cancer diagnoses account for innumerable healthcare visits 
each year; however, there are no exact estimates for small cell lung carcinoma versus NSCLC. It 
is estimated that around 228,000 newly diagnosed cases of lung cancer are treated each year, 
accounting for about 14% of cancer diagnoses.1,5 Further, around 159,000 lung cancer deaths 
occurred in the United States in 2013 alone.1 The commonality of the disease coupled with 
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staggering healthcare costs and time is indicative of the fact that NSCLC treatment is a topic that 
is relevant to both patients and the physician assistant practice. 
The most important risk factor related to the development of NSCLC is smoking, 
including both first- and second-hand smoke. Other risk factors include environmental exposures, 
such as radon, asbestos, and air pollution, and a personal or family history of lung cancer. 
Although lung cancer may present as an incidental finding on imaging, the most common 
presenting symptoms include worsening cough, chest pain, or hemoptysis.1 Due to the fact that 
NSCLC frequently presents as metastatic disease, clinicians also look for signs of distant 
metastases, such as malaise, weight loss, dyspnea, and hoarseness.1 
Vascular endothelial growth factor (VEGF), which is commonly associated with NSCLC, 
promotes tumor growth and progression via angiogenesis. Bevacizumab is a monoclonal anti-
VEGF antibody that inhibits angiogenesis, thereby slowing the growth of carcinoma. 
Bevacizumab has shown clinical improvement in various cancers, including NSCLC.2 
Consequently, bevacizumab as adjunctive treatment has not been studied comprehensively as to 
which combination of traditional chemotherapy would provide the most benefit, nor has it been 
studied extensively as a monotherapy for NSCLC. 
There are several therapeutic treatment options available for patients with NSCLC; yet, 
results of standard treatment are often poor because most NSCLC diagnoses present as 
metastatic disease, rather than localized.2 In NSCLC, surgery is the most theoretically curative 
treatment for patients. Postoperative chemotherapy and/or radiation therapy may provide 
additional benefit. Patients who present with advanced stage disease have shown improvement 
from chemotherapy and/or epidermal growth factor receptor (EGFR) kinase inhibitors. 1 The 
standard treatment options for patients with stage IIIb NSCLC include postoperative 
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chemotherapy, combination chemotherapy and radiation therapy, and/or radiation therapy alone. 
The first-line treatment options for patients with stage IV NSCLC are combination 
chemotherapy, combination chemotherapy with bevacizumab, or EGFR tyrosine kinase 
inhibitors. Other traditional treatment options for stage IV NSCLC include endobronchial laser 
therapy and/or brachytherapy or external-beam radiation therapy.1 Each option mentioned plays 
a role in treatment depending on the stage and histologic grade of the NSCLC. The use of 
bevacizumab has been shown to be effective in the treatment of grade IIIb and IV NSCLC when 
combined with specific types of adjuvant chemotherapy. This selective evidence-based medicine 
(EBM) review evaluated RCTs to examine the effectiveness of bevacizumab as adjuvant 
chemotherapy in the treatment of NSCLC. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not bevacizumab 
(avastin) is safe and effective as adjuvant chemotherapy for adult patients with stage IIIb or IV 
NSCLC. 
METHODS 
 Specific selection criteria for the RCTs were used for this EBM review. The population 
chosen was adults > 18 years old with stage IIIb or IV NSCLC. The intervention utilized in each 
study was bevacizumab adjuvant chemotherapy. Comparisons were made between traditional 
chemotherapy, such as paclitaxel-carboplatin, erlotinib, or cisplatin-gemcitabine, plus 
bevacizumab and traditional chemotherapy plus placebo or chemotherapy alone. Outcomes 
measured were based on patient oriented evidence that matters (POEMs), specifically, the overall 
survival (OS) and progression-free survival (PFS). The study types included three RCTs 
comparing bevacizumab adjuvant chemotherapy to traditional treatment options. 
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 Key words used in the searches were “non-small cell lung cancer,” “avastin,” 
“bevacizumab,” and “adjuvant chemotherapy.” All articles were published in peer-reviewed 
journals and in the English language. The author researched the articles via PubMed, Medline, 
and OVID. Articles were selected based on their relevance to the author’s EBM question, in 
addition to the inclusion of study outcomes that mattered to the patients (POEMs). Studies that 
were RCTs published after 1996 and studies with patients over the age of 18 years old with stage 
IIIb or IV NSCLC were included. Studies with patients under the age of 18 years old and/or with 
stage I through IIIa NSCLC were excluded. Additional demographics and characteristics related 
to each study are included in Table 1. The statistics used in the studies to evaluate the patient 
outcomes included ABI, HR, NNT, and RBI.2,3,6 
OUTCOMES MEASURED 
The outcomes measured were based on OS and/or PFS. OS was defined as time from 
randomization to death from any cause. PFS was defined as time from randomization to first 
documented disease progression or death on study treatment, whichever occurred first. Outcomes 
were evaluated using stratified Cox proportional hazard models to estimate hazard ratios, 
comparing how often survival occurred with the addition of bevacizumab to how often it 
occurred with traditional chemotherapy alone. Event-time distributions were estimated using the 
Kaplan-Meier method.2,3,6 
RESULTS 
 The data collected from the Sandler et al and Reck et al RCTs was in dichotomous form, 
while data collected from the Herbst et al RCT was in continuous form. Herbst et al2 and Reck et 
al6 compared traditional chemotherapy plus bevacizumab to traditional chemotherapy plus 
placebo, while Sandler et al3 compared traditional chemotherapy plus bevacizumab to traditional 
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chemotherapy alone. 
Table 1 – Demographics and characteristics of included studies 
Study Type # Pts Age 
(yrs) 
Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Herbst, 
20112 
Double-
blind 
RCT 
636 18+ 
y/o 
Patients 18+ 
y/o who had 
SCC and had 
received 
neoadjuvant 
or adjuvant 
therapy for 
stage I-IIIa 
disease with 
ECOG 
performance 
score of 0 to 1 
Pts with an MI 
within the past 6 
mo, UA, CHF, 
arrhythmia, PVD, 
uncontrolled HTN, 
h/o of hemoptysis, 
presence of a tumor 
invading blood 
vessels, bleeding 
diathesis, another 
invasive CA within 
5 yrs prior to 
randomization, 
current use of 
aspirin or NSAIDs, 
previous tx with 
anti-EGFR or anti-
VEGF agents, 
surgery 28 d before 
study 
0 Erlotinib plus 
bevacizumab 
 
Reck, 
20096 
Double-
blind 
RCT 
1043 18+ 
y/o 
Patients 18+ 
y/o who had 
stage IIIb or 
IV NSCLC 
with ECOG 
performance 
score of 0 to 1 
Pts with SCLC, h/o 
hemoptysis, CNS 
metastasis, h/o 
thrombotic d/o, 
current use of 
aspirin, CVD, 
uncontrolled HTN, 
surgery 4 wk before 
study, presence of a 
tumor invading 
blood vessels 
0 Cisplatin and 
gemcitabine 
plus 
bevacizumab 
 
Sandler, 
20063 
RCT 878 18+ 
y/o 
Patients 18+ 
y/o who had 
stage IIIb or 
IV NSCLC 
with ECOG 
performance 
score of 0 to 1 
Pts with 
hemoptysis, CNS 
metastasis, bleeding 
diathesis, current 
use of NSAIDs, 
major surgery 28 d 
before enrollment, 
CVD, uncontrolled 
HTN 
0 Paclitaxel and 
carboplatin 
chemotherapy 
plus 
bevacizumab 
De Kleine, Bevacizumab and Chemotherapy, 6 
 Herbst et al2 conducted a randomized controlled double-blind clinical trial that involved 
enrolling 636 patients at 177 study sites in 12 countries from June 8, 2005 to April 16, 2008.  319 
patients were randomly assigned to the traditional chemotherapy (erlotinib) plus bevacizumab 
group, and 317 patients were assigned to the erlotinib plus placebo group. Median follow-up 
time for patients in either group was 19 months after initial enrollment date. The investigators 
reported no difference in OS between the groups, as median OS was around 9.2 to 9.3 months in 
both placebo and bevacizumab groups. Hazard ratios were estimated through use of an 
unstratified Cox model, which produced a HR of 0.97 with a 95% CI (0.80-1.18) and p-value of 
0.7583 (Table 2).2 PFS appeared to differ significantly among the bevacizumab and placebo 
groups in this study. Herbst et al2 reported results as 3.4 months in the bevacizumab group 
compared to 1.7 months in the control group. However, results were not reported as statistically 
significant due to the fact that fixed-sequence testing was used in order to control the overall type 
I error rate.2 
Table 2 – Efficacy of erlotinib plus bevacizumab in comparison to erlotinib plus placebo 
measured via overall survival hazard ratio2 
 Bevacizumab 
Median OS, 
months (IQR) 
Placebo 
Median OS, 
months (IQR) 
Hazard Ratio P-value 95% CI 
Overall 
Survival (OS) 
9.2, (3.8 – 
20.2) 
9.3, (4.1-21.6) 0.97 0.7583 (0.80-1.18) 
 Reck et al6 conducted a RCT that involved randomly assigning 1,043 patients at 150 
study sites in 20 countries between February 2005 and August 2006 to three different groups.  
347 patients were randomly assigned to the traditional chemotherapy (cisplatin-gemcitabine) 
plus placebo group, 345 patients were assigned to the cisplatin-gemcitabine plus low-dose 
bevacizumab group, and 351 patients were assigned to the cisplatin-gemcitabine plus high-dose 
bevacizumab group. Traditional chemotherapy was administered every three weeks for up to six 
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cycles, and bevacizumab or placebo was administered every three weeks until either the disease 
progressed or adverse events were intolerable. The investigators reported insufficient follow-up 
time for OS analysis.6 Conversely, a considerable difference in PFS was noted in both of the 
low- and high-dose bevacizumab groups compared to the control. Median PFS was around 6.7 
months in the group assigned to low-dose bevacizumab and 6.5 months in the group assigned to 
high-dose bevacizumab, compared to 6.1 months in the chemotherapy plus placebo group. 
Hazard ratios were determined via Kaplan-Meier estimates, which produced a low-dose 
bevacizumab HR of 0.75 with a 95% CI (0.62-0.91), and p-value of 0.003. The high-dose 
bevacizumab HR was 0.82 with a 95% CI (0.68-0.98), and p-value 0.03 (Table 3). 6 
Table 3 – Efficacy of cisplatin and gemcitabine plus either low- or high-dose bevacizumab in 
comparison to cisplatin and gemcitabine plus placebo measured via progression-free survival 
hazard ratio6 
 Low-dose 
Bevacizumab 
Median PFS 
High-dose 
Bevacizumab 
Median PFS 
Placebo 
PFS 
Hazard Ratio P-Value 95% CI 
    Low-
Dose 
High-
Dose 
Low-
Dose 
High-
Dose 
Low-
Dose 
High-
Dose 
Progression-
Free 
Survival 
(PFS) 
6.7 months 6.5 months 6.1 
months 
0.75 0.82 0.003 0.03 (0.62-
0.91) 
(0.68-
0.98) 
 Sandler et al3 conducted a randomized controlled double-blind clinical trial that involved 
enrolling 878 patients from July 2001 to April 2004.  434 patients were randomly assigned to the 
traditional chemotherapy (paclitaxel-carboplatin) plus bevacizumab group, and 444 patients were 
assigned to the paclitaxel-carboplatin alone group. The traditional chemotherapy was 
administered every three weeks for six cycles, and bevacizumab was administered every three 
weeks until either the disease progressed or adverse events were intolerable. The investigators 
reported a considerable difference in OS between the groups. Median OS was around 12.3 
months in the group assigned to traditional chemotherapy plus bevacizumab, compared to 10.3 
De Kleine, Bevacizumab and Chemotherapy, 8 
months in the chemotherapy-alone group. Hazard ratios were determined via Kaplan-Meier 
estimates, which produced a HR of 0.79 with a 95% CI (0.67-0.92) and p-value of 0.003.3 PFS 
also appeared to be statistically significant when comparing the bevacizumab and chemotherapy-
alone groups in this study. Sandler et al3 reported results as 6.2 months in the bevacizumab group 
compared to 4.5 months in the control group. Hazard ratios were estimated by use of an 
unstratified Cox model, which produced a HR of 0.66 with a 95% CI (0.57-0.77) and p-value < 
0.001 (Table 4).3 
Table 4 – Efficacy of paclitaxel and carboplatin plus bevacizumab in comparison to paclitaxel 
and carboplatin alone measured via overall survival hazard ratio3 
 Bevacizumab 
1-year OS, 2-
year OS 
Chemotherapy 
alone 1-year 
OS, 2-year OS 
Hazard Ratio P-value 95% CI 
Overall 
Survival (OS) 
51%, 23% 44%, 15% 0.79 0.003 (0.67-0.92) 
Table 5 shows relative benefit increase (RBI) for overall survival, which was statistically 
significant in both Herbst et al2 and Sandler et al3 studies, with the addition of bevacizumab to 
traditional chemotherapy. For the Herbst et al2 study, the RBI was calculated to be 32% and 
absolute benefit increase was 11%. Numbers needed to treat (NNT) was calculated as 9, meaning 
that nine patients need to be treated with bevacizumab compared to traditional chemotherapy 
alone in order to have one person have improved overall survival. For the Sandler et al3 study, 
the RBI was calculated to be 16% and absolute benefit increase was 7%. NNT was calculated as 
14, meaning that fourteen patients need to be treated with bevacizumab compared to traditional 
chemotherapy alone in order to have one person benefit from this type of treatment. 
Table 5 – Benefit of bevacizumab on overall survival 
 CER  EER RBI ABI NNT 
Erlotinib plus bevacizumab in comparison to erlotinib plus 
placebo (Herbst et al)2 
34% 45% 32% 11% 9 
Paclitaxel and carboplatin plus bevacizumab in comparison to 
paclitaxel and carboplatin alone (Sandler et al)6 
44% 51% 16% 7% 14 
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Adverse events (AE) were also measured in each of the RCTs. Herbst et al2 reported 42% 
of the bevacizumab group compared to 36% of the control group with a serious AE > grade 3. 
Reck et al6 reported similar findings between the bevacizumab group and the control group with 
regards to AEs. The investigators of this study reported 81% of the high-dose bevacizumab and 
76% of the low-dose bevacizumab compared to 75% of the control group with a serious AE > 
grade 3.6 Finally, Sandler et al3 reported several significant AEs that occurred more often in the 
bevacizumab group, compared to the control group (Table 6). 
Table 6 – Adverse events reported with administration of bevacizumab3 
Adverse Event Bevacizumab Group 
# of patients (%) 
Control Group 
# of patients (%) 
P-Value 
Neutropenia 109 (25.5) 74 (16.8) 0.002 
Hypertension 30 (7) 3 (0.7) <0.001 
Proteinuria 13 (3.1) 0 (0) <0.001 
Headache 13 (3.0) 2 (0.5) 0.003 
Bleeding event 19 (4.4) 3 (0.7) <0.001 
Table 7 shows relative risk increase (RRI) for adverse events (AE), which was 
statistically significant in the Sandler et al3 study. Numbers needed to harm (NNH) was 
calculated for each significant AE. The most significant result, headache, had an NNH that was 
calculated as 40, meaning that forty patients need to be treated with bevacizumab compared to 
traditional chemotherapy alone in order to have one person experience AE of headache. 
Table 7 – Risk of bevacizumab on adverse events 
 CER EER RRI ARI NNH 
Neutropenia 16.8% 25.5% 52% 8.7% 11 
Hypertension 0.7% 7% 900% 6.3% 16 
Proteinuria 0% 3.1% N/A 3.1% 32 
Headache 0.5% 3% 500% 2.5% 40 
Bleeding event 0.7% 4.4% 529% 3.7% 27 
DISCUSSION 
 This systematic review investigated three RCTs for the safety and efficacy of 
bevacizumab as adjuvant chemotherapy for adult patients, 18 years of age and older, with stage 
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IIIb or IV NSCLC. The study by Herbst et al2 failed to find a significant difference in OS or PFS 
between subjects using adjuvant bevacizumab and those using traditional chemotherapy. While 
the Reck et al6 study was unable to assess OS; the investigators did find that PFS was 
significantly improved with the addition of bevacizumab to traditional chemotherapy. The study 
by Sandler et al3 established that the addition of bevacizumab to traditional chemotherapy has 
statistically significant survival benefits in patients with NSCLC. 
 Bevacizumab is FDA approved to treat NSCLC, metastatic colorectal cancer, metastatic 
HER2 negative breast cancer, and metastatic renal cell carcinoma.7 It is also approved for 
second-line treatment of glioblastoma. The drug has a black box warning for gastrointestinal 
perforations, wound healing complications, and hemorrhage.7 Most importantly, fatal pulmonary 
hemorrhage has been reported in patients with NSCLC treated with chemotherapy plus 
bevacizumab.7 This significant AE was demonstrated in a small percentage of patients in each of 
the RCTs, which is important when considering future studies.2,3,6 
 Limitations were present in each RCT, which affect their validity regarding the question 
of concern. Herbst et al2 reported that crossover effects from using a potentially active 
chemotherapeutic agent, bevacizumab, were not monitored throughout the study. Furthermore, 
Herbst et al2 utilized subsequent lines of therapy during follow-up more often in the control 
group than in the bevacizumab group, which most likely confounded the comparison of OS 
between the two groups. In both the Reck et al6 and Sandler et al3 studies, confounding variables 
such as favorable prognostic features of the patient population may have influenced the favorable 
outcome of increased OS and PFS. For example, Reck et al6 revealed that the overall patient 
population was younger with a higher incidence of less severe stage IIIb NSCLC as compared to 
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similar studies regarding bevacizumab and NSCLC. Finally, each of the three RCTs 
acknowledged financial support by Genentech and Roche, the marketers of bevacizumab.2,3,6 
CONCLUSION 
 From the research performed and results obtained, the evidence is inconclusive and 
conflicting to support the use of bevacizumab as adjuvant chemotherapy for stage IIIb or IV 
NSCLC. Herbst et al2 found that the addition of bevacizumab to traditional chemotherapy 
(erlotinib) does not improve OS or PFS in NSCLC patients. However, Reck et al6 found that the 
addition of bevacizumab to traditional chemotherapy (cisplatin-gemcitabine) significantly 
improves only PFS rates.  Finally, Sandler et al2 found that the addition of bevacizumab to 
traditional chemotherapy (paclitaxel-carboplatin) has statistically significant OS and PFS 
benefits. 
 With inconsistencies and differing results among the three RCTs, further research would 
be helpful to confirm or negate the question of whether bevacizumab is actually beneficial as 
adjuvant chemotherapy. More importantly, stricter guidelines should be applied to future 
research regarding patient population characteristics, as well as the addition of bevacizumab to 
one specific traditional chemotherapy. In addition to researching the efficacy and safety of 
bevacizumab as adjuvant chemotherapy, it would be advantageous to study the efficacy and 
safety of bevacizumab as monotherapy. Comparisons can be made between the use of the drug as 
an adjunctive treatment versus the use of the drug as a single drug treatment for NSCLC. 
Continued research on bevacizumab for NSCLC will be beneficial to patients who are refractory 
to initial treatments of the disease. Further research is warranted to obtain more conclusive data. 
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